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Abstract
Based on immunomodulatory, osteogenic, and pro-angiogenic properties of adipose-
derived stem cells (ASCs), this study aims to assess the safety and efficacy of ASC-derived
cell therapies for clinical indications. Two autologous ASC-derived products were proposed
to 17 patients who had not experienced any success with conventional therapies: (1) a scaf-
fold-free osteogenic three-dimensional graft for the treatment of bone non-union and (2) a
biological dressing for dermal reconstruction of non-healing chronic wounds. Safety was
studied using the quality control of the final product (genetic stability, microbiological/myco-
plasma/endotoxin contamination) and the in vivo evaluation of adverse events after trans-
plantation. Feasibility was assessed by the ability to reproducibly obtain the final ASC-
based product with specific characteristics, the time necessary for graft manufacturing, the
capacity to produce enough material to treat the lesion, the surgical handling of the graft,
and the ability to manufacture the graft in line with hospital exemption regulations. For 16
patients (one patient did not undergo grafting because of spontaneous bone healing), in-
process controls found no microbiological/mycoplasma/endotoxin contamination, no obvi-
ous deleterious genomic anomalies, and optimal ASC purity. Each type of graft was repro-
ducibly obtained without significant delay for implantation and surgical handling was always
according to the surgical procedure and the implantation site. No serious adverse events
were noted for up to 54 months. We demonstrated that autologous ASC transplantation can
be considered a safe and feasible therapy tool for extreme clinical indications of ASC prop-
erties and physiopathology of disease.
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Introduction
Cell therapy has recently gained more interest from scientists and clinicians. It offers new ther-
apeutic tools and hope for patients who have not experienced success with classical treatments
by proposing "personalized" therapies for selected indications. In some cases (for example,
radiotherapy, diabetes, burns, etc.), fibrotic tissue is observed with a lack of tissular vasculariza-
tion and irrigation, poor stromal cell recruitment, and a paucity of growth factors. In these
cases, cell therapy is proposed to restore the physiology of the injured tissue by the induction of
tissue vascularization [1], immunomodulatory effects [2,3], and secretion of growth factors
promoting tissue remodeling and regeneration [4–7].
Among the different sources for cell therapy, mesenchymal stem cells (MSCs) are the most
studied because they offer the advantage of being isolated from adult donors and demonstrate
the capacity to differentiate into multiple tissues, including bone, fat, skeletal muscle, and carti-
lage [8,9]. MSCs were first isolated from bone marrow by Friedenstein more than 50 years ago
[10]. More recently, a new source of MSCs was proposed, the adipose tissue [11]. Adipose mes-
enchymal stem cells (ASCs) are easily accessible in abundant quantities and can be collected by
a minimally invasive procedure. Adipose tissue-derived stem cells showed properties similar to
those of bone marrow-derived MSCs and showed even better isolation reproducibility and
higher proliferation capacity [12,13]. Moreover, ASCs demonstrated four properties that could
be helpful in cell therapy: angiogenicity [1,13–16], osteogenicity [13,17], immunomodulation
[18], and promotion of tissue remodeling [4,5,16].
First, to initiate tissue remodeling, the product needs to be vascularized for appropriate oxy-
gen and nutrients to be supplied from the blood stream. In this context, mesenchymal stem
cells, and mainly ASCs, are of particular interest because they are able to secrete growth factors
promoting angiogenesis (VEGF, HGF, PDGF, FGFb) [7,15,16,19,20]. Interestingly, these pro-
angiogenic properties are maintained after osteodifferentiation [13]. Therefore, the use of
ASCs is highly justified to induce the revitalization of the tissue, both in bone and skin recon-
struction. Moreover, ASCs were also shown to secrete bone morphogenic protein 2, which is
involved in bone remodeling and bone formation [21]. In addition, ASCs were shown to
secrete fibroblast growth factor-2, a pro-angiogenic factor involved in the wound healing pro-
cess [22,23], keratinocyte growth factor, which is a growth factor with paracrine effects on cells
implied in wound healing [24,25] and insulin-like growth factor 1, which is important in
wound healing because it promotes wound re-epithelialization and granulation tissue forma-
tion [26–29]. Therefore, in this study, ASCs were seeded on a collagen membrane to promote
wound healing by the induction of tissue vascularization and tissue remodeling.
Cases of hospital exemption treated in this study all had physiopathology of disease charac-
terized by a lack of spontaneous tissue remodeling, principally attributable to a lack of growth
factors required to initiate tissue vascularization, stem cell recruitment, proliferation, and dif-
ferentiation and to control inflammation. In this context, the properties of ASCs were perfectly
adequate for the physiological effects of the graft and the needs of the patient.
In response to a specific request from surgeons confronted by patients with "untreatable"
pathologies and failure of conventional treatments, we tried to take advantage of these four proper-
ties of ASCs to develop new therapeutic approaches. Two types of cellular therapy products were
required for bone non-union and non-healing chronic wounds. There was a need for the develop-
ment of a malleable three-dimensional (3D) cell therapy product with osteogenic and angiogenic
properties for bone reconstruction in orthopedic surgery [13,17] and a suturable biological dress-
ing for the promotion of angiogenesis in the wound bed and dermal regeneration [16].
These products were developed to treat specific patients with end-stage pathologies in the
context of hospital exemption. The safety and feasibility remain the first questions to be studied.
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The term "safety" implies minimizing the risk/benefit ratio, which takes into account the
improvement of the quality of life expected for treated patients and the risks associated with
the procedure. These risks include the following: microbiological safety of the product; genetic
stability of the product; absence of adverse events after cell procurement and implantation;
homing of transplanted cells to the site of injury; absence of ectopic tissue formation; in vivo
oncogenic/tumorogenic safety of the cellular product; and control of host immune response
against the transplanted cells. Although risk reduction can be achieved by the use of immuno-
suppressive drugs, serious side effects of these medications dramatically increase the risk com-
ponent of the ratio. However, this problem is overcome by the use of cells of autologous origin.
The feasibility of cell therapy includes the possibility of manufacturing the product in com-
pliance with cell and tissue banking regulations and current good manufacturing practice prin-
ciples, which requires complete control and traceability of all processes from the procurement
of the raw materials to the delivery of the grafts, the reproducibility of graft manufacturing, the
characteristics of the product, and strong quality assurance and quality control services.
In addition, the harvesting procedure should be simple and as non-invasive as possible. Fea-
sibility of the implantation of the cell therapy product must be demonstrated in terms of easy
handling (by the surgeon) and implantability in a dedicated implantation site.
Therefore, the aim of this study was to evaluate the safety and feasibility of two cell therapy
products derived from ASCs in the context of hospital exemption.
Materials and Methods
Design of the study
Two autologous cell therapy products were studied: (1) a scaffold-free osteogenic 3D graft for
the treatment of bone non-union (congenital pseudarthrosis/intercalary bone allograft implan-
tation after tumor resection) and (2) a biological dressing for dermal reconstruction of non-
healing chronic wounds (radionecrosis, drepanocytosis, and vasculitis).
These two cell therapy products were manufactured from autologous ASCs. Fatty tissue was
harvested from the patient by a simple and rapid procedure under local anesthesia (lipoaspi-
rate) or during a surgical procedure (pieces of fatty tissue were taken during tumor biopsy for
diagnosis) and sent to the clean room for treatment. ASCs were then isolated, expanded in
vitro, and, if necessary, differentiated and/or seeded on a scaffold. Once the culture process was
completed, the cellular product was re-implanted in the patient (Fig 1).
This study was performed according to the Belgian Ministry of Health (AFMPS) guidelines
for hospital exemption (and obtained the authorization by the national central authorities as
the clinical number studies: ATMP-HE004 and ATMP-HE005). All procedures for tissue pro-
curement and clinical studies (for adult and children patients) were approved by the Ethical
Committee of the Medical Faculty (Université Catholique de Louvain) as the national authori-
zation number: B40320108280 and B40320108542. All patients (adults and parents of the chil-
dren) signed the consent to participate in the study after verbal and written information were
received from the principal investigator of the study. All consent forms were included and
archived in the Case Report Form for each patient (and for a duration of 30 years).
All materials were obtained from Lonza (Verviers, Belgium), Sigma-Aldrich (St. Louis, MO,
USA), or Invitrogen (Carlsbad, CA, USA) unless otherwise noted.
Clinical data of the patients
A total of 17 patients were included in the study (Fig 1) and 19 grafts were manufactured.
Eleven patients received a tridimensional stem cell autograft during orthopedic surgery.
One additional patient with enchondromatosis did not undergo implantation because she
Adipose Stem Cell Therapy: Safety and Feasibility
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presented with spontaneous consolidation. The orthopedic cases included six oncology patients
(five males and one female): one patient with chondrosarcoma (OLS010) who received an allo-
graft after tumor resection more than 2 years before being included in the study and five patients
with bone tumors (three osteosarcomas: OLS001, OLS004, OLS005) and two Ewing sarcomas
(OLS003 and OLS006 characterized by several clonal cytogenetic alterations) who underwent
preoperative chemotherapy for a mean duration of 2 and 12 months before tumor resection. In
these cases, anatomical reconstitution was performed with a metallic prosthesis and a human
osteochondral allograft, respectively (Table 1). In addition, after failure of conventional therapies
such as surgery (e.g., curettage, elongation, Fassier-Duval Telescopic system, intramedullary fixa-
tion, and Ilizarov fixation), iliac crest autograft, and demineralized bone matrix alone, five
patients with non-union of bone due to congenital pseudarthrosis (n = 4; OLS002, OLS007,
OLS009, OLS011) or acquired pseudarthrosis (in the context of erythroblastopenia, n = 1;
Fig 1. Autologous grafts manufactured. The schema of autologous ASC-derived cell therapy includes adipose tissue harvesting from a patient under local
anesthesia. A: Bone non-union following allograft. B: Chronic wound on drepanocytosis. C: fatty tissue harvesting. D: ASC isolation. E: Expansion in culture
plates. F: 3D osteogenic-like structure. G: Biological dressing. The table indicates the growth factors secreted by human ASCs. Results shown are the ratio of
growth factors expressed in hypoxia (0.1%O2) versus normoxia (21%O2). VEGF = vascular endothelial growth factor; HGF = hepatocyte growth factor;
PDGF = platelet derived growth factor; FGFb = fibroblast growth factor b.
doi:10.1371/journal.pone.0139566.g001
Table 1. Clinical/manufacturing data associated with the implantation of the manufactured 3D osteogenic-like autologous grafts.
Patient
ID
Clinical Indication Clinical History and Previous
Intervention
Age
(yr)
Gender Harvesting
Site
Quantity of
Fatty Tissue
Harvested
Time to
Obtain the
Graft (d)
OLS001 Non-metastatic osteosarcoma grade
III, left distal femur
Chemotherapy 11 M Per-op 2.1 g 81
OLS002 Right tibio-ﬁbular congenital
pseudarthrosis without
neuroﬁbromatosis
Two nailings and one Ilizarov
compression
11 F Per-op 1.9 g 119
OLS003 Ewing's sarcoma, left diaphyseal
femur
Bone non-union after allograft,
reconstruction after tumor
resection (1.5 yr previously)
9 M Per-op 9.68 g 133
OLS004 Diaphyseal osteosarcoma grade III,
left femur
3 sessions of thermocoagulation,
curettage, trepanation, and
chemotherapy
47 F Peri-umb 16.8 g 48
OLS005 Osteosarcoma, left proximal tibia Chemotherapy, 14-cm resection,
and osteochondral allograft
reconstruction
11 M Per-op 0.3 g 80
OLS006 Ewing sarcoma, right proximal tibia Chemotherapy 12 M Peri-umb 1.1 g 143
OLS008 Iatrogenic non-union
+ eryblastopenia (Blackfan Diamond
disease)
1 yr before ASCs isolation: tibial
elongation and osteotomy
13 M Per-op 7 g 111
OLS009 Congenital pseudarthrosis (type I
neuroﬁbromatosis), left ulna (+ radial
shortening)
1.5 yr before ASCs isolation:
pseudarthrosis resection, iliac
crest graft, ulna elongation
6 F Peri-umb 1 g 117
OLS010 Isolated chondrosarcoma grade I-II
backdrop, left acetabulum to pelvic
bone-ischiopubic branch
Chondrosarcoma resection and
allograft (2.5 yr previously)
63 M Peri-umb 9.8 g 108
OLS011 Congenital atrophic non-union (type
IV Crawford classiﬁcation), right tibia
and ﬁbula
2 yr before ASCs isolation:
synostose resection, recurrent
osteotomies, and iliac graft
9 M Per-op 2.5 g 109
OLS007 Congenital atrophic non-union (type
IV Crawford classiﬁcation), right tibia
and ﬁbula
1.5 yr before ASCs isolation:
fracture after fall
6 M Per-op 0.6 g 130
Per-op: per operation. Peri-umb: peri-umbilical.
doi:10.1371/journal.pone.0139566.t001
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OLS008) were given the option of receiving the osteogenic-like 3D structure (Table 1). One
patient with congenital pseudarthrosis underwent grafting twice (OLS007 and OLS011).
Seven cases of non-healing chronic wounds (>8 months of bad evolution) untreatable by
classic therapies such as hyperbaric oxygen therapy, skin grafting, and active dressings (evolu-
tion of 13 to 46 months) were treated with a biological dressing made of autologous ASCs. One
male patient with a chronic wound attributable to radionecrosis after irradiation for hystiosar-
coma underwent grafting twice with the biological dressing (SBD001, SBD002). A dressing was
also grafted to one male patient and to one female patient with non-healing ulcerations on dre-
panocytosis (SBD003) and systemic lupus erythemotosus (SBD004), respectively. One male
patient presented with radionecrotic chronic wounds after irradiation for liposarcoma
(SBD005) and another male patient had chronic ulcers after a full-thickness burn (SBD006).
The lower limb wounds of this last case were covered by pedicled flaps, but a chronic wound
developed at the edge of the area (evolution over 3 years). Finally, one male type 2 diabetic
patient with multiple complications (retinopathy, microalbuminuria, macroangiopathy, neu-
ropathy) was treated for his chronic wounds with the biological dressing (SBD007) (Table 2).
Graft manufacturing
Fatty tissue procurement and ASC isolation and expansion. Grafts were manufactured
in the Endocrine Cell Therapy Unit (Center of Tissue and Cell Therapy, Cliniques
Table 2. Clinical/manufacturing data associated with the implantation of the manufactured biological dressings.
Patient
ID
Clinical Indication Clinical History and Previous
Intervention
Age
(yr)
Gender Time
Course
(mo)
Quantity of
Fatty Tissue
Harvested (g)
Total
Time of
Culture
(d)
Surface of
the Wound
Treated
(cm2)
SBD001 Chronic wound,
radionecrosis
Radionecrosis after adjuvant
radiotherapy after sarcoma resection
46 M 8 59 83 12
SBD002 Chronic wound,
radionecrosis
Radionecrosis after adjuvant
radiotherapy after sarcoma resection
47 M 8 21.9 86 12
SBD003 Chronic wound,
drepanocytosis
Homozygote drepanocytosis, 4 large
supra malleolar wounds, no success
with skin autograft
21 M 46 7.8 175 >250
SBD004 Chronic wounds,
vasculitis (lupus
erythematosus
disseminated)
Systemic lupus erythematosus
complicated by 4 large supra
malleolar wounds, no success with
skin autograft
33 F 27 20.8 131 >200
SBD005 Chronic wound,
radionecrosis
Liposarcoma 44 yr ago with adjuvant
radiotherapy, distal arteriopathy,
chronic ulcer treated, no success
with skin autograft
67 M 32 4.2 64 24
SBD006 Chronic wounds, full-
thickness burn
For 46 yr, chronic ulcers in distal
lower limbs after full-thickness burn,
early coverage by pedicled ﬂap after
failure of primary skin autografts, no
success with skin autograft
72 M >36 8.6 127 ~26
SBD007 Chronic wounds,
diabetes (type 2)
Type 2 diabetes for 13 yr with
multiple complications, 10
hospitalizations in the past 7 yr for
soft tissue infections (secondary to
leg and diabetic foot ulcers), no
success with skin autograft
71 M >240 8.6 35 200
Adipose tissue was harvested in the peri-umbilical zone for each patient.
doi:10.1371/journal.pone.0139566.t002
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Universitaires Saint-Luc, Brussels, Belgium), which is recognized by the Belgian Federal
Agency for Medicines and Health Products as a clinical laboratory for processing ASC isola-
tion. All ASC isolation and expansion procedures were performed in grade A air-laminated
flow located in a grade B clean room (validated annually by ICCE SA, Elsene, Belgium, in
accordance with the BelgiumMinistry of Health recommendations and European directives,
regulation no. 1394/2007 for advanced cell therapy products). The environment for cellular
culture was controlled by weekly particle counting (in static and dynamic conditions; Lasair II
Particle Counter; Particle Measuring Systems Germany GmbH, Darmstadt, Germany) and
microbiological testing at each manipulation, as recorded in the graft report.
A mean of 9.7 ± 13.7 g of fatty tissue was harvested from each patient after submitting
informed consent and serologic screening (anti-HIV-1, anti-HIV-2, anti-HCv, anti-HBc, anti-
HBs, Ag HBs, CMV Ig, syphilis) and nucleic acid testing (HIV-1, HCV, HBV) by a simple sub-
cutaneous biopsy or by lipoaspiration using the Coleman technique [30]. Adipose tissue was
kept for a maximum of 90 min at 2°C to 8°C until tissue digestion and ASC isolation in line
with the Belgian Federal Agency for Medicines and Health Products recommendations and the
ISO 9001–2008 quality management system. Fatty tissue was digested with GMP collagenase
!8 PZ U/ml (Serva Electrophoresis GmbH, Heidelberg, Germany) reconstituted in Hank’s
balanced salt solution (with calcium and magnesium ions) at 37°C for 60 min. After digestion,
the collagenase was inactivated in proliferation medium made of DMEM supplemented with
10% heat-inactivated fetal bovine serum (FBS), L-glutamine (2 mM), and antibiotics (penicillin
100 U/ml and streptomycin 100 μg/ml). Collected tissue was centrifuged for 10 min at 450×g.
After filtration through a 500-μmmesh screen (Haver, Battice, Belgium), the tissue was centri-
fuged for 10 min at 450×g and then resuspended in proliferation medium. This initial passage of
the primary cells was referred to as passage 0. After 24 to 48 h of incubation at 37°C at 5% CO2,
cell cultures were washed with phosphate-buffered saline (PBS) and maintained, after sequential
trypsinizations, in proliferation media up to passage 4. The selection of ASCs was performed
based on their capacity to adhere to plastic culture flasks. Quality controls confirmed the mesen-
chymal phenotype and the purity of ASC preparations (see “Graft properties” section below).
Specific cellular therapy product manufacturing and implantation
Osteogenic-like 3D structure. At passage 4, ASCs were incubated (in 150 cm2 culture
flask) in osteogenic medium composed of the proliferation medium supplemented with dexa-
methasone (1 μM), sodium ascorbate (50 μg/ml), and sodium dihydrophosphate (36 mg/ml).
After 15 to 18 days of ASC incubation, demineralized bone matrix (DBM) was added (10 mg/ml)
to create the tridimensional structure. Human DBM (cortical bone particles, 200–700 μm,
treated with HCl 0.6 N for 3 h and sterilized with 25 kGy by gamma irradiation; provided by
the University Tissue Bank, University Clinical Hospital Saint-Luc, Brussels, Belgium), which
is known for its osteoinductive properties, was added (10 mg/ml) to create the tridimensional
structure.
The tridimensional graft was rinsed three times with transplantation medium (CMRL; Med-
iatec Inc., Manassas, VA, USA) without phenol red and without antibiotics or sera. The graft
was finally placed in a sterile culture flask enclosed in three sterile plastic bags. The graft was
then transferred at room temperature, for less than 15 min, to the operating room for implan-
tation (Fig 1).
In case of tumor resection, the 3D graft was placed directly at the junction between the
native host bone and the bone allograft or the growing prosthesis. In case of bone non-union,
the tridimensional osteogenic graft was modeled to the ideal size of the bone defect and placed
directly into the hole without any fixation material.
Adipose Stem Cell Therapy: Safety and Feasibility
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Biological dressing. At confluency at passage 3 or passage 4 (depending on the size of the
wound), cells in proliferation medium were trypsinized, resuspended in 400 μl DMEM, and
seeded on a human acellular collagen matrix (HACM) [31–33]. Fascia lata from selected
donors were procured according to European/Belgian legislation regarding human body mate-
rials after human tissue donor screening based on clinical history, serological tests, and micro-
biological testing. The human fascia lata tendon was prepared as already described by using a
process developed by the Tissue Bank of Cliniques Universitaires Saint Luc (Brussels, Belgium)
[31] to obtain HACM containing no chemical residues (acetone/H2O2), with pH of the water
last used for rinsing being between 7.00 and 7.84 and having less than 10% residual moisture,
and sterilized by gamma irradiation at 25,000 Gy (Sterigenics, Fleurus, Belgium). HACM and
ASCs were maintained in culture in 150 cm2 flasks until the collagen matrix was covered by
ASCs (classically 3–4 weeks) [34]. On the day of implantation, the composite graft was rinsed
three times with transplantation media (CMRL; Mediatec, Manassas, VA, USA).The dressing
was finally placed in a sterile culture flask embedded in three sterile plastic bags with ASCs
loaded on the upper side of the HACM. The graft was then transferred at room temperature to
the operating room for implantation (Fig 1). In seven patients, wound debridement was per-
formed by hydrosurgery (Versajet1; Smith & Nephew, Zaventem, Belgium) before the
implantation to ensure a minimally contaminated wound bed. The composite graft was cut to
an ideal size and oriented with the cell layer directly in contact with the wound surface. The
HACM was then fixed with non-absorbable sutures. The composite graft integration was clini-
cally assessed twice weekly. Vaselinated dressings were applied and changed daily.
Safety
Microbiological safety. During the whole process of graft manufacturing, environmental
and microbiological controls were performed. Environmental controls were performed during
each manipulation of the cells by air sedimentation plates and total particle count. In addition,
surface controls with contact plates in the clean room were performed weekly as well as before
and after steps of ASC isolation and graft packaging. Microbiological testing was repeatedly
performed at each media change (twice per week during the entire manufacturing of the graft)
for aerobia, anaerobia, moisture, and yeast by BACTEC assays according to European Pharma-
copeia 2.6.1. In addition, the sterility of the transport medium was checked after implantation
in the operating room. Finally, endotoxin and mycoplasma assays were performed according
to European Pharmacopeia 2.6.14 by Texcell SA (Evry, France) on the last cellular samples col-
lected before graft delivery.
Microbiological testing was repeatedly performed at each media change (twice per week
during the entire manufacturing of the graft) for aerobia, anaerobia, moisture, and yeast by
BACTEC assays. In addition, total particle count was recorded during all manipulations.
Genetic stability
Cytogenetic stability was studied by conventional karyotyping and fluorescent in situ hybrid-
ization (FISH) analyses to assess the oncogenic safety of cellular therapy products. Metaphase
chromosomes were obtained according to standard protocols from cells at passage 1 and pas-
sage 4 and osteodifferentiated cells [9]. When possible, 20 reverse Trypsin-Wright G-banded
metaphases were analyzed and karyotypes were reported according to the 2013 International
System for Human Cytogenetics Nomenclature (ISCN 2013). Clonal aberrations were defined as
at least two mitoses with the same chromosomal gain or structural anomaly and at least three
mitoses with the same chromosomal loss. Fluorescent in situ hybridization was performed
according to standard protocols [35] to detect aneusomies and aneuploidies (systematically
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researched by FISH for at least two loci) and the initial tumor-associated genomic abnormalities.
In total, 17 different loci were analyzed on 11 different chromosomes with a classical commercial
probe and two homemade BAC probes (S1 Table: Probes used for FISH analysis).
The thresholds were calculated following inverse beta law with a confidence interval of
99.9%.
Adverse events
Safety was studied in terms of adverse events (local or systemic) with clinical (inflammation,
wound infection) and biological (C-reactive protein, fibrinogen, white blood cell count) assess-
ments (at day 0 and day 3). The long-term safety of the 3D osteogenic structure was investi-
gated by imaging (X-ray or magnetic resonance imaging) between 1 and 54 months post-
transplantation to assess any secondary ectopic malignant tissue development. Post-operative
clinical examinations allowed evaluation of the long-term safety of the biological dressing. A
biopsy of the zone treated with the biological dressing was also performed between 4 and 8
weeks post-implantation for histological analysis (neovascularization [Masson’s trichrome],
inflammation [CD3/CD68 immunostainings], and fibrosis).
Feasibility
The feasibility study was based on the ability to reproducibly obtain the desired graft (i.e., a 3D
osteogenic-like structure from autologous ASCs and allogenic DBM or a biological dressing
made of autologous ASCs and allogenic collagen matrix) in a sufficient amount to treat the
lesion. The time between adipose tissue procurement and graft implantation was also assessed.
The capability of developing quality control tests able to confirm the mesenchymal origin of
ASCs and the optimal manufacture of the graft was evaluated. Surgical handling of the graft
and the easy implantation procedure were considered. Finally, the ability to manufacture the
graft in conditions in accordance with the Belgian quality guidelines (Belgian Federal Agency
of Drugs and Health Product) was evaluated.
Graft properties
From the 13th patient, at the end of the proliferation phase (at passage 4), the mesenchymal
lineage of ASCs was confirmed by flow cytometry. Cells were stained with saturating amounts
of monoclonal CD90, CD44, CD45, CD73, and CD105 antibodies (BD Pharmingen, San
Diego, CA, USA) conjugated with phycoerythrin or fluorescein isothiocyanate. At least 10,000
events were analyzed by flow cytometry (FACScan; BD Biosciences, Erembodegem, Belgium)
with CellquestPro software. Percentages of cells expressing markers were calculated with a
threshold corresponding to 95% of control cells. To confirm their multipotency, ASCs under-
went adipogenesis, osteogenesis, and chondrogenesis by differentiation in specific adipocyte,
osteoblast, and chondroblast induction media, respectively, as already described [13,14].
Alzarin red, Alcian blue (AppliChem GmbH, Darmstadt, Germany), and oil red staining were
used to confirm osteogenic, chondrogenic, and adipogenic phenotypes, respectively, after
differentiation.
A biopsy specimen (minimum of 8 mm3) of the osteogenic-like 3D structure harvested the
day of the implantation was fixed in 4% paraformaldehyde overnight. Serial sections (5 μm
thick) were made for staining with osteocalcin (anti-osteocalcin OC4-30 monoclonal mouse
antibody at a dilution of 1:100; ABCAM, Cambridge, UK), extracellular matrix (by Masson’s
trichrome), and mineralization (by Von Kossa) on each sample for all types of differentiated
and non-differentiated cells (negative control). Quantification of the cellular portion, the neo-
synthesized extracellular matrix, and the DBM fragments via the calculation of the ratio
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[(DBM:extracellular matrix)/cell] was performed to evaluate the quality of the graft (the ratio
should be between -1 and +1 to ensure sufficient quality) [17].
For the biological dressing, the cellular covering of the HACM was controlled (by an inde-
pendent pathologist) 1 week before transplantation by a biopsy specimen of the composite
graft fixed in 4% paraformaldehyde overnight and stained by hematoxylin and eosin and DAPI
(40,60-diamidino-2-phénylindol; fluorescent molecule binding to adenine and thymine bases of
DNA).
Surgical handling of the graft
The easy handling of the graft and the capacity of the cellular therapy product implantation
were evaluated by the surgeon. The graft should be easily manipulated and placed at the
implantation site by the surgeon. Tridimentional ASC autografts should be malleable to fill
bone (manually or by the use of a trochar), and the size and shape of the biological dressing
should be adaptable and suturable on the wound bed by the surgeon.
Results
Safety
Microbiological safety. Environmental controls, including laboratory surface controls,
particle count, and air sedimentation, were performed during all steps of graft manufacturing.
Three results (Fig 2) were not below the authorized limits. Staphylococcus aureus, Staphylococ-
cus epidermidis, and corynebacterium contaminations of the transport medium were noted
after implantation; however, the medium was sterile when it left the production unit, indicating
contamination in the operating room.
Genetic stability
Genetic studies (karyotype and/or FISH) were available for 15 different manufactured grafts
(not performed in four grafts). First, of the six oncologic patients, the initial tumor-associated
genomic anomalies were not recovered after cell proliferation and differentiation.
For nine grafts, genetic results were informative for stages of “end of proliferation” and “dif-
ferentiation” (S2 Table: Genetic analysis results on manufactured grafts). No aberrations were
detected at these stages in four grafts (OLS003, OLS005, OLS009, and OLS011). Genetic abnor-
malities induced during the proliferation phase disappeared or were reduced after differentia-
tion in two cases (OLS002 and OLS010). For OLS010, a stable balanced reciprocal
translocation was detected in 52% of cells, as was trisomy 7 in 7% of cells at the end of the pro-
liferation phase. At the end of the differentiation phase, the translocation was reduced to 31%
of cells and trisomy 7 disappeared.
Two different translocations involving chromosome 15 (8% of cells) and trisomy 7 in 20%
of cells were detected in proliferation and differentiation phases, respectively, in patient
OLS006 (S2 Table). However, cells were maintained in the proliferation phase for 3 additional
months without any abnormalities detected. In addition, the initial anomaly disappeared after
culture. A very minor deletion of the short of chromosome 3 was detected in the differentiation
phase of OLS008 (2 out of 40 analyzed cells, which is theoretically under the threshold for the
definition of a chromosomal clonal aberration).
Peri-/post-operative security (short- and long-term). No notable adverse events were
noted during and after the implantation procedure. Three cases of infection were noted. How-
ever, these infections affected the skin or the synthetic material, but the cellular product was
not implicated (Tables 3 and 4).
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One patient with osteosarcoma showed recurrence of her tumor. However, anatomopathological
reports showed that tumoral cells were present at the resection margins, indicating an insufficient
initial tumor resection. In addition, because the implanted cells lost their oncogenic phenotype
after differentiation, the implanted cells are seemingly not responsible for this recurrence.
In contrast, to date, for the 17 other grafts for orthopedic surgery and for the biological
dressing, no formations of ectopic tissues or neoformation of tumors were observed for a maxi-
mum of 54 months and 38 months, respectively (Fig 3).
Feasibility
In all patients, a mean of 9.7 g (range, 0.3–59 g) of adipose tissue was easily harvested without
any notable complication. When culture conditions were optimal (no excess of blood during
Fig 2. Quality controls of the manufactured grafts. Environmental controls including air sedimentation and total air particle count were performed during
each manipulation of the product. Microbiological controls (sterility) were performed on harvesting transport medium, on cell culture medium at each cell
medium change, and on the implantation transport medium. In addition, mycoplasma and endotoxins were measured on the last medium change before
implantation. Fluorescence-activated cell sorting and histological assessments allowed characterization of the product. *Staphylococcus aureus,
Staphylococcus epidermidis, and corynebacterium striatum contaminations were detected. However, the contamination occurred in the operating room and
did not affect the product. Fluorescence-activated cell sorting analyses were not performed for bone reconstruction for the first eight patients or for dermal
reconstruction for the first four patients. A: Von Kossa staining of the 3D osteogenic-like structure (*DBM particle; arrows: ASCs + extracellular matrix). B:
Alizarin red (RA) coloration of osteodifferentiated ASCs. C: Osteocalcin staining of the 3D osteogenic-like structure (*DBM particle; arrows: ASCs
+ extracellular matrix). D: DAPI staining of ASCs seeded on the fascia lata (*fascia lata; arrows: ASCs on the scaffold).
doi:10.1371/journal.pone.0139566.g002
Table 3. Complication data associated with the implantation of the manufactured biological dressings.
Patient
ID
Maximum
Follow-up (mo)
Short-Term Complications Long-Term Complications
OLS001 54 Delayed wound healing (at 11 mo, scar OK), no infection No prolonged inﬂammation, no infection, no neoplastic
development
OLS002 2 Optimal wound healing, no infection No prolonged inﬂammation, no infection, no neoplastic
development
OLS003 1 Optimal wound healing, no infection No prolonged inﬂammation, no infection, no neoplastic
development
OLS004 27 1 mo: Lateral external surface, left tight oozing (abscess
femoral scar)
Subcutaneous collection (Staphylococcus aureus) easily
treated, scar OK at 8 wk, no infection, no neoplastic
development
OLS005 48 2 mo: Small skin necrosis on the internal scar, evolution
toward a ﬁbrin crust, wide debridement + care until
complete healing, no infection
No prolonged inﬂammation; 10 mo: resection following cellulite
on the outer side of the leg (without collection); no neoplastic
development
OLS006 48 6 wk: Optimal wound healing, no infection No prolonged inﬂammation, no infection, no neoplastic
development
OLS007 37 Follow-up 2 wk to 3 yr: beautiful scar, no infection No prolonged inﬂammation; 9 mo: redness of leg on old port
pin, free ﬂowing, clean, crust formed, CRP <0.1, normal white
blood cells; no obvious signs of infection, no neoplastic
development
OLS011 13 4 mo: Optimal wound healing, no infection No prolonged inﬂammation; 4 mo: plate and nail fracture,
reconstruction by autologous vascularized ﬁbula at 6 mo; 6 mo:
perioperative S. epidermidis detection, no neoplastic
development
OLS008 29 Not determined No prolonged inﬂammation, no infection, no neoplastic
development
OLS009 10 Optimal wound healing, no infection No prolonged inﬂammation, no infection; 6 mo: redness; 7 mo:
decrease in external inﬂammatory signs; 10 mo: slightly
elevated CRP and white blood cells to 14,000; 10.5 mo:
swelling next to the plate; 11 mo: S. aureus sensitive to oxacillin
OLS010 47 Optimal wound healing, no infection No prolonged inﬂammation, no infection, no neoplastic
development
doi:10.1371/journal.pone.0139566.t003
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AT procurement and 5% CO2 in the cell culture incubator), ASC isolation, proliferation, and
manufacturing of the three grafts types were reproducibly performed in 100% of cases.
A mean of 107 ± 28 days was needed to obtain a tridimensional osteogenic graft (Table 1),
whereas the biological dressing was obtained after a mean of 100 ± 47 days (Tables 1 and 2). In
100% of cases, the timing imposed by the surgeon was adequate.
Table 4. Complication data associated with the implantation of the manufactured 3D osteogenic-like graft.
Patient
ID
Maximum Follow-up
(mo)
Short-Term Complications Long-Term Complications
SBD001 22 Complete healing maintained up to now (>22 mo), no infection No prolonged inﬂammation, no infection, no
neoplastic development
SBD002 22 Complete healing maintained up to now (>22 mo), no infection No prolonged inﬂammation, no infection, no
neoplastic development
SBD003 35 Healing for >6 mo (recurrence or poor control of the systemic
disease), no infection
No prolonged inﬂammation, no infection, no
neoplastic development
SBD004 38 Healing for 2 mo (recurrent/systemic disease), no infection No prolonged inﬂammation, no infection, no
neoplastic development
SBD005 9 Complete healing, no infection No prolonged inﬂammation, no infection, no
neoplastic development
SBD006 7 Partial healing (half of the treated area), no infection No prolonged inﬂammation, no infection, no
neoplastic development
SBD007 6 No notable wound healing, no complications No prolonged inﬂammation, no infection, no
neoplastic development
doi:10.1371/journal.pone.0139566.t004
Fig 3. Pre-, peri-, and post-operative pictures of the treated cases. A: Chronic wound (12 cm2) on radionecrosis (SBD001). B: Autologous biological
dressing before implantation. C: Implantation of the biological dressing (SBD001); note that this was easily suturable. D: Follow-up at 5 months after
implantation (SBD002) (follow-up at 22 months was similar) (9). E: Bone defect on congenital pseudarthrosis (OLS002). F: Autologous osteogenic-like 3D
structure before implantation. Implantation of the osteogenic-like 3D structure (G) manually (OLS002) or (H) through a trocar (OLS003). I: Follow-up at 46
months after implantation (OLS006).
doi:10.1371/journal.pone.0139566.g003
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Grafts were manufactured in a sufficient amount to fill the defects (for osteogenic-like struc-
tures) or cover the entire wound surface, even for large wounds (>200 cm2 for biological
dressings).
ASCs were confirmed as stem cells by a positive shift in CD90, CD44, CD73, and CD105
and by no shift in CD45 expression by flow cytometry. ASCs presented a fibroblast phenotype
in the proliferation medium. The multipotency of ASCs was confirmed by their differentiation
in adipocytes, osteocytes, and chondrocytes.
All 12 osteogenic-like 3D structures presented osteocalcin expression, synthesis of extracel-
lular matrix, and mineralization (by Von Kossa) on each sample for all types of differentiated
and non-differentiated cells (negative control). The histomorphological score (DBM—extracel-
lular matrix)/number of cells) was always between -1 and 1, as required [17].
The hematoxylin and eosin and DAPI staining confirmed the cellular covering of the
HACM.
The Belgian quality guidelines (Belgian Federal Agency of Drugs and Health Product and
ISO9001) were followed during the processing of the whole graft from the procurement of the
adipose tissue (informed consent, viral screening of the donor, and absence of microorganisms
in the harvested tissue) to the delivery of the graft (conformity of quality controls, timing of
manufacturing).
The osteogenic-like 3D grafts formed prehensile structures easily malleable by the surgeon
to fill bone defects, manually or through the use of a trocar. However, these grafts were stable
enough to avoid any dissemination outside their implantation sites (Fig 3).
The biological dressings were able to be manipulated and their shapes were adaptable by the
surgeon. The dressings were resistant and suturable on the wound beds (Fig 3).
Discussion
This study demonstrates (i) the safety of cell therapy comprising differentiated and undifferen-
tiated ASCs, (ii) the capacity to reproduce two distinct cell therapy products available for two
different surgical applications, and (iii) the importance of the pathophysiology of the disease in
the context of cell therapy.
The first question addressed in this study was to ensure the safety of the procedure, even in
an oncologic field. No notable undesirable effects were observed in grafted patients after ASC
collection or during short-term or long-term periods after the implantation of the product.
However, there are challenges concerning the genetic safety of cell therapy. Although malig-
nant transformation of MSCs has not been noted to date in clinical trials using culture-
expanded autologous and allogenic human MSCs [36–40], controversy exists concerning the
potential of spontaneous transformation of MSC after prolonged ex vivo culture. In vitro stud-
ies have shown that MSC expansion may be associated with chromosomal alterations [41] and
genetic instability and lead to tumor development in treated animals [42]. However, it was
demonstrated that ASCs, up to passage 16, do not present clonal transformation [16], whereas
in the present study cells were not used for more than five passages. Aneusomies such as tri-
somy 7 were detected in several cases. It is known to be induced in proliferative cultured
human MSCs and to have no obvious impact on the safety of the cells, as previously reported
by Tarte et al. [43]. The cells from this patient were maintained in culture for 3 additional
months without any anomalies detected. Minor tetraploidy and translocations were also noted
in the proliferation phase in one and two patients, respectively, but it was reduced or disap-
peared after differentiation. Aneuploidy, such as tetraploidy, is known to occur in cultured
MSCs without any oncogenic significance [36]. Genetic analyses using both techniques (the
pangenomic karyotype and targeted FISH on at least two different loci) did not show the major
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expansion of a clone at the differentiation phase, although some aberration appeared at the
proliferation phase. A hypothesis explaining the loss of abnormal genotype after differentiation
could be that proliferative cells with genetic alteration lose their capability to differentiate, lead-
ing to a natural positive selection of normal cells. Moreover, the low resolution of the karyotype
does not preclude the absence of induced oncogenic mutations through the process of culture.
Because validation of the use of a gene panel has not been already accomplished by NGS, the
karyotype remains the reference technique for pan-genomic analysis in search of minor clones
coupled with FISH. Imaging procedures and clinical examinations did not detect any tumor
formation due to cell transplantation up to 4 years post-implantation.
The second concern of this study was the feasibility of the procedure, including the ade-
quacy for clinical demand, the reproducibility of the procedure, and the compliance with cur-
rent regulatory requirements. In addition to their intrinsic physiological properties, grafts
should be easily implantable by the surgeon. Both types of grafts were easily handled by the sur-
geon for treating bone and skin lesions. The tridimensional ASC autograft was easily malleable
to fill bone defects. It was prehensile with forceps and could be placed through a trocar. The
implantation of ASCs for the treatment of chronic wounds was limited by the difficulty in
maintaining cell contact with the wound. Therefore, ASCs were seeded on a collagen scaffold
with a size and shape adaptable by the surgeon and suturable on the wound bed. The collagen
support is resorbable in approximately 6 weeks, thus preparing the wound for a prospective
skin graft. Improvements of the biological dressing need to be made to simultaneously promote
both dermal and epidermal reconstruction. The grafts were reproducibly manufactured in a
defined time. However, the latest is relatively long and should be reduced by improving culture
conditions.
The cellular therapy products manufactured should be clinical grade. In this study, although
the current good manufacturing practice was not fully achieved, Belgian national recommen-
dations were followed. The human and raw materials were traced; all manipulations were thor-
oughly documented and regular quality controls were performed for the products and their
environment. These controls allowed confirmation of the sterility of the graft and the detection
of several dysfunctions and graft exclusion before implantation to guarantee patient safety. Ten
grafts were rejected because the quality controls were not optimal. After analysis, it appeared
that too much blood in the fatty tissue harvested inhibited ASC proliferation and led to the
selection of another cell phenotype. In addition, poor regulation of the levels of carbon dioxide
in the incubator prevented the formation of the 3D structure (pH higher than 7.6) (data not
shown).
Finally, the adequacy between the expected theoretical effects of the graft, based on growth
factors secreted by ASCs (VEGF, BMP2, FGF-2, KGF, IGF-1), and the observed clinical efficacy
need to be verified. It appeared that ASC-based cell therapy products demonstrated optimal
efficacy in clinical indications, where they were used to treat a local lesion in an unfavorable
environment (lack of tissue vascularization, poor cellular recolonization, growth factors deple-
tion, inflammation), but in the absence of a systemic physiopathology. The 3D osteogenic-like
structure allowed bone consolidation for up to 4 years without any notable complications in
oncologic patients with tumor resection (data not published). These non-consolidations after
tumor resection are local lesions not associated with systemic pathologies or unfavorable con-
dition (except the chemotherapeutic treatment). In contrast, more variable results were noted
in patients with systemic diseases, such as congenital pseudarthrosis, characterized by an
absence of a local favorable environment (low level of local and systemic growth factors, such
as fibroblast growth factor 2) [44] or Blackfan-Diamond syndrome (erythroplastopeny). Simi-
larly, the use of a biological dressing to treat chronic wounds allowed complete healing of
wounds after radionecrosis or burn, which are local lesions, although it was not indicated in
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the case of systemic blood/vascular diseases (drepanocytosis, vasculitis, diabetes) [16]. The spe-
cific indications of each cell product should therefore be investigated, probably by selecting
local lesions not associated with systemic pathologies.
In conclusion, we have demonstrated that cell therapy products obtained from autologous
ASCs are feasible and safe for several reasons. The grafts could be reproduced in the desired
form, in a defined timeframe, and in a sufficient amount to treat the lesion. Quality control
tests were able to confirm the mesenchymal origin of ASCs, the optimal manufacture of the
graft, the genetic stability of the cells, and the microbiological safety of the product. Clinical
grade production guidelines were followed. The possibility of harvesting adipose tissue for all
patients as well as the easy surgical handling of the graft and the easy implantation procedures
were confirmed. The procedures were not associated with serious side effects or adverse events.
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